Rx00042 - Bevacizumab


Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00042
Primary Indication
Secondary Indication

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
adult glioblastoma Glioblastoma 2018 2018 2018 1999.467 0 0.0
metastatic carcinoma of the rectum metastatic colorectal cancer 7288 7288 7288 553.639 0 0.0
non-squamous non-small cell lung cancer Non-squamous non-small cell lung cancer 6927 6927 6927 582.492 0 0.0
metastatic colorectal cacner metastatic colorectal cancer 7288 7288 7288 553.639 0 0.0
metastatic carcinoma of the colon metastatic colorectal cancer 659 869 7288 419.849 0 0.0

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
ADULT GLIOBLASTOMA GLIOBLASTOMA 3.1e-291 ABCB1, ABHD16A, ACAA1, ACAD11, ADAM19, ADAM33, ADAP1, ALOX12, ALOX12B, ALOX15, ALOX15B, ALOX5, ALOX5AP, ALOXE3, APC, APEX1, APOA2, AQP1, ARFRP1, ATAD2, ATG9B, ATM, ATP12A, ATP2B1, ATP2C2, ATRX, AURKA, AURKB, BCL2, BPI, BRAF, BRCA1, C1D, C1QA, C1QB, C1QBP, C1QC, C1RL, C1S, C2, C3, C4BPA, C4BPB, C5, C5AR1, C6, C7, C8A, C8B, C8G, C9, CACNA1A, CACNA1C, CACNA1H, CACNA2D3, CAT, CBS, CCDC26, CCL1, CCL11, CCL13, CCL18, CCL2, CCL20, CCL24, CCL26, CCL5, CCL7, CCL8, CCR1, CCR3, CCR4, CCR6, CCR7, CCR8, CCR9, CD14, CD180, CD209, CD46, CD55, CD93, CDK4, CDKN2A, CDKN2B, CFB, CHEK2, CHI3L1, CHRNA3, CHRNA9, CLCA1, CLCA2, CNTNAP1, CORO1C, CRP, CTNNB1, CX3CR1, CXCR1, CXCR2, CYBA, CYP1A1, CYP21A2, DAB2, DAXX, DEF6, DEFA3, DEFA4, DEFA5, DEFA6, DEFB1, DEFB118, DEFB119, DEFB126, DEFB127, DHX33, DLG5, DMBT1, EGF, EGFR, EME1, ERBB2, ERBB3, ERBB4, ERCC1, ERCC2, ERCC6, EXO1, F5, FCER1A, FCER1G, FCER2, FCGR2A, FCGRT, FGF2, FGFR1, FLJ90680, FLT3, FOXJ2, GGCT, GLS, GNAS, GNB3, GPR108, GPR44, GPX1, GRIK4, GRIN2B, GRM1, GSTM1, GSTM3, GSTP1, GSTT1, H2AFX, H3F3A, HES7, HGF, HIF1A, HLA-A, HLA-B, HLA-C, HLA-DRB1, HRAS, HSPA6, ICAM1, ICAM2, ICAM3, ICAM4, ICAM5, IDH1, IDH2, IGF1, IGF1R, IGF2, IGF2R, IGFBP3, IL10, IL11RA, IL13, IL17C, IL4, IL4R, IL8, INSL3, IRAK2, IRAK3, IRAK4, ITGB2, ITPR3, JAK2, JAK3, KCNA4, KCNB2, KCND2, KCNG3, KCNH1, KCNH5, KCNJ15, KCNK1, KDR, KIT, KLK1, KLK15, KLK2, KLK4, KLK6, KLK7, KLKB1, KRAS, LBP, LMAN1, LPO, LRIG2, LRIG3, LRRC4B, LTBR, LY6G6D, LY96, MAL, MASP1, MASP2, MBL2, MBP, MDM2, MEFV, MGMT, MIF, MIR196A2, MLH1, MMP1, MMP2, MPO, MSH2, MSH6, MTHFR, MTR, MUC6, MUC7, MYC, MYD88, NAB2, NAT2, NBN, NCF2, NCF4, NDUFS2, NEIL3, NF1, NFKB1, NFKBIA, NIPAL4, NMUR1, NOD1, NOD2, NOS1, NOS2, NOS3, NQO1, NTRK2, NUDT6, OR10J3, PDCD10, PDGFRA, PFKFB2, PHLDB1, PKD1L2, PPARG, PTEN, PTGDR, PTGS2, PTPN11, PTPRD, RAC1, RAC2, RAD51L3-RFFL, RAVER1, RBBP6, RBFOX1, RECQL4, REN, RET, RFC1, RPS4XP13, RTEL1, RYR2, RYR3, S100B, SCAF4, SCGB1A1, SCN1B, SCN3A, SCN3B, SCN5A, SCN9A, SCNN1A, SDHAF2, SDHB, SDHC, SDHD, SECTM1, SELE, SELP, SELPLG, SENP3, SERPINB2, SERPINB3, SERPINC1, SERPINE1, SERPING1, SERPINI1, SLC11A1, SLC12A5, SLC1A2, SLC2A11, SLC2A4RG, SLC5A7, SLC8A1, SLC9A1, SLC9A2, SLC9A4, SOCS1, SOCS2, SOCS3, SOCS4, SOD1, SOD2, SOD3, SSBP2, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, STIM2, STK19, TCN2, TERT, TICAM1, TLR1, TLR10, TLR2, TLR3, TLR4, TLR6, TLR9, TMCO6, TNFRSF18, TNFSF18, TNFSF9, TOLLIP, TP53, TRAM1, TRAP, TREM2, TRPM5, TRPV5, TSLP, TWF1, TWF2, TYK2, UGT1A1, VCAM1, VEGFA, VHL, WDHD1, XDH, XRCC1, XRCC3, ZBTB46, ZGPAT, ZNF76, ZP1

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01XC07
Category:
Angiogenesis Inhibitors
Classification:
Kingdom:
Organic Compounds
Superclass:
Organic Acids
Class:
Carboxylic Acids and Derivatives
Subclass:
Amino Acids, Peptides, and Analogues
Indication:
As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
Pharmacodynamics:
Bevacizumab is an antineoplastic agent and prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metatstatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and...
Click to show more...
Description:
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions o...
Click to show more...
Mechanism:
Bevacizumab contains human framework regions with antigen binding regions of a humanised murine antibody that binds to VEGF. Bevacizumab is produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system i...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Not Available from DrugBank


Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org